203 related articles for article (PubMed ID: 27004402)
1. Oncogenic AKT1(E17K) mutation induces mammary hyperplasia but prevents HER2-driven tumorigenesis.
Mancini ML; Lien EC; Toker A
Oncotarget; 2016 Apr; 7(14):17301-13. PubMed ID: 27004402
[TBL] [Abstract][Full Text] [Related]
2. Stat5 regulates the phosphatidylinositol 3-kinase/Akt1 pathway during mammary gland development and tumorigenesis.
Schmidt JW; Wehde BL; Sakamoto K; Triplett AA; Anderson SM; Tsichlis PN; Leone G; Wagner KU
Mol Cell Biol; 2014 Apr; 34(7):1363-77. PubMed ID: 24469394
[TBL] [Abstract][Full Text] [Related]
3. Disruption of epithelial architecture caused by loss of PTEN or by oncogenic mutant p110α/PIK3CA but not by HER2 or mutant AKT1.
Berglund FM; Weerasinghe NR; Davidson L; Lim JC; Eickholt BJ; Leslie NR
Oncogene; 2013 Sep; 32(37):4417-26. PubMed ID: 23085752
[TBL] [Abstract][Full Text] [Related]
4. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
5. PI3K-p110α mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers.
Wang Q; Liu P; Spangle JM; Von T; Roberts TM; Lin NU; Krop IE; Winer EP; Zhao JJ
Oncogene; 2016 Jul; 35(27):3607-12. PubMed ID: 26500061
[TBL] [Abstract][Full Text] [Related]
6. Activation of Akt1 accelerates carcinogen-induced tumorigenesis in mammary gland of virgin and post-lactating transgenic mice.
Wu Y; Kim J; Elshimali Y; Sarkissyan M; Vadgama JV
BMC Cancer; 2014 Apr; 14():266. PubMed ID: 24742286
[TBL] [Abstract][Full Text] [Related]
7. Estrogen receptor beta growth-inhibitory effects are repressed through activation of MAPK and PI3K signalling in mammary epithelial and breast cancer cells.
Cotrim CZ; Fabris V; Doria ML; Lindberg K; Gustafsson JÅ; Amado F; Lanari C; Helguero LA
Oncogene; 2013 May; 32(19):2390-402. PubMed ID: 22751110
[TBL] [Abstract][Full Text] [Related]
8. PKCtheta promotes c-Rel-driven mammary tumorigenesis in mice and humans by repressing estrogen receptor alpha synthesis.
Belguise K; Sonenshein GE
J Clin Invest; 2007 Dec; 117(12):4009-21. PubMed ID: 18037997
[TBL] [Abstract][Full Text] [Related]
9. Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer.
Feigin ME; Akshinthala SD; Araki K; Rosenberg AZ; Muthuswamy LB; Martin B; Lehmann BD; Berman HK; Pietenpol JA; Cardiff RD; Muthuswamy SK
Cancer Res; 2014 Jun; 74(11):3180-94. PubMed ID: 24662921
[TBL] [Abstract][Full Text] [Related]
10. PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system.
Beaver JA; Gustin JP; Yi KH; Rajpurohit A; Thomas M; Gilbert SF; Rosen DM; Ho Park B; Lauring J
Clin Cancer Res; 2013 Oct; 19(19):5413-22. PubMed ID: 23888070
[TBL] [Abstract][Full Text] [Related]
11. The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas.
Shoji K; Oda K; Nakagawa S; Hosokawa S; Nagae G; Uehara Y; Sone K; Miyamoto Y; Hiraike H; Hiraike-Wada O; Nei T; Kawana K; Kuramoto H; Aburatani H; Yano T; Taketani Y
Br J Cancer; 2009 Jul; 101(1):145-8. PubMed ID: 19491896
[TBL] [Abstract][Full Text] [Related]
12. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells.
Higgins MJ; Beaver JA; Wong HY; Gustin JP; Lauring JD; Garay JP; Konishi H; Mohseni M; Wang GM; Cidado J; Jelovac D; Cosgrove DP; Tamaki A; Abukhdeir AM; Park BH
Cancer Biol Ther; 2011 Feb; 11(3):358-67. PubMed ID: 21124076
[TBL] [Abstract][Full Text] [Related]
13. Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors.
Tikoo A; Roh V; Montgomery KG; Ivetac I; Waring P; Pelzer R; Hare L; Shackleton M; Humbert P; Phillips WA
PLoS One; 2012; 7(5):e36924. PubMed ID: 22666336
[TBL] [Abstract][Full Text] [Related]
14. PTEN deficiency in a luminal ErbB-2 mouse model results in dramatic acceleration of mammary tumorigenesis and metastasis.
Schade B; Rao T; Dourdin N; Lesurf R; Hallett M; Cardiff RD; Muller WJ
J Biol Chem; 2009 Jul; 284(28):19018-26. PubMed ID: 19435886
[TBL] [Abstract][Full Text] [Related]
15. Tumors with AKT1E17K Mutations Are Rational Targets for Single Agent or Combination Therapy with AKT Inhibitors.
Davies BR; Guan N; Logie A; Crafter C; Hanson L; Jacobs V; James N; Dudley P; Jacques K; Ladd B; D'Cruz CM; Zinda M; Lindemann J; Kodaira M; Tamura K; Jenkins EL
Mol Cancer Ther; 2015 Nov; 14(11):2441-51. PubMed ID: 26351323
[TBL] [Abstract][Full Text] [Related]
16. Activation of Akt (protein kinase B) in mammary epithelium provides a critical cell survival signal required for tumor progression.
Hutchinson J; Jin J; Cardiff RD; Woodgett JR; Muller WJ
Mol Cell Biol; 2001 Mar; 21(6):2203-12. PubMed ID: 11238953
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of resistance to endocrine therapy in breast cancer: the important role of PI3K/Akt/mTOR in estrogen receptor-positive, HER2-negative breast cancer.
Araki K; Miyoshi Y
Breast Cancer; 2018 Jul; 25(4):392-401. PubMed ID: 29086897
[TBL] [Abstract][Full Text] [Related]
18. Landscape of Phosphatidylinositol-3-Kinase Pathway Alterations Across 19 784 Diverse Solid Tumors.
Millis SZ; Ikeda S; Reddy S; Gatalica Z; Kurzrock R
JAMA Oncol; 2016 Dec; 2(12):1565-1573. PubMed ID: 27388585
[TBL] [Abstract][Full Text] [Related]
19. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
20. p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-neu oncogene-dependent breast tumorigenesis.
Cabodi S; Tinnirello A; Di Stefano P; Bisarò B; Ambrosino E; Castellano I; Sapino A; Arisio R; Cavallo F; Forni G; Glukhova M; Silengo L; Altruda F; Turco E; Tarone G; Defilippi P
Cancer Res; 2006 May; 66(9):4672-80. PubMed ID: 16651418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
